Klaria Pharma Holding AB (publ.) (STO:KLAR)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.9500
+0.0240 (2.59%)
Feb 10, 2026, 5:29 PM CET
Market Cap227.77M +74.8%
Revenue (ttm)10.05M +303.8%
Net Income-46.02M
EPS-0.29
Shares Out245.98M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume191,558
Average Volume672,760
Open0.9300
Previous Close0.9260
Day's Range0.9300 - 1.0000
52-Week Range0.3960 - 1.8100
Beta1.62
RSI49.71
Earnings DateFeb 20, 2026

About STO:KLAR

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; and Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. The company is also involved in commercialization and sale of... [Read more]

Sector Healthcare
Founded 2014
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol KLAR
Full Company Profile

Financial Performance

In 2024, STO:KLAR's revenue was 2.25 million, a decrease of -73.41% compared to the previous year's 8.45 million. Losses were -47.75 million, 33.4% more than in 2023.

Financial Statements